William M. Sikov

5.7k total citations · 3 hit papers
93 papers, 3.4k citations indexed

About

William M. Sikov is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William M. Sikov has authored 93 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 51 papers in Cancer Research and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William M. Sikov's work include Breast Cancer Treatment Studies (44 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (27 papers). William M. Sikov is often cited by papers focused on Breast Cancer Treatment Studies (44 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (27 papers). William M. Sikov collaborates with scholars based in United States, Germany and Canada. William M. Sikov's co-authors include Mehra Golshan, George Somlo, Eric P. Winer, Donald A. Berry, Clifford A. Hudis, Lisa A. Carey, Constance Cirrincione, W. Fraser Symmans, Elisa Port and Charles M. Perou and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

William M. Sikov

87 papers receiving 3.3k citations

Hit Papers

Impact of the Addition of Carboplatin and/or Bevacizumab ... 2014 2026 2018 2022 2014 2018 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
  2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    2018 516 citations William M. Sikov, Mehra Golshan et al. profile →
  3. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancer
    2019 235 citations Nathaniel Braman, Prateek Prasanna et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William M. Sikov United States 26 2.3k 1.7k 660 590 553 93 3.4k
Günther Gruber Switzerland 15 1.7k 0.7× 1.8k 1.0× 556 0.8× 513 0.9× 596 1.1× 24 3.2k
Frédérique Penault–Llorca France 10 2.3k 1.0× 1.4k 0.8× 734 1.1× 707 1.2× 823 1.5× 20 3.3k
Yasuaki Sagara Japan 25 1.8k 0.8× 1.2k 0.7× 656 1.0× 422 0.7× 383 0.7× 109 2.9k
Malcolm Hayes Canada 27 1.4k 0.6× 1.2k 0.7× 626 0.9× 756 1.3× 943 1.7× 92 3.2k
Tibor Tot Sweden 32 2.1k 0.9× 1.5k 0.9× 871 1.3× 407 0.7× 1.4k 2.4× 103 4.0k
Maria Schwaederlé United States 28 1.5k 0.7× 1.7k 1.0× 1.1k 1.7× 1.0k 1.7× 611 1.1× 43 3.2k
Yun Gong United States 35 1.9k 0.8× 1.1k 0.6× 1.0k 1.6× 1.1k 1.9× 411 0.7× 118 3.6k
Charles Coutant France 34 1.5k 0.6× 1.6k 0.9× 558 0.8× 472 0.8× 723 1.3× 205 4.4k
Takayuki Kinoshita Japan 34 1.9k 0.8× 2.1k 1.2× 737 1.1× 900 1.5× 1.1k 2.0× 174 4.2k
C. Bourgier France 31 1.2k 0.5× 1.2k 0.7× 1.1k 1.6× 649 1.1× 475 0.9× 163 3.1k

Countries citing papers authored by William M. Sikov

Since Specialization
Citations

This map shows the geographic impact of William M. Sikov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William M. Sikov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William M. Sikov more than expected).

Fields of papers citing papers by William M. Sikov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William M. Sikov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William M. Sikov. The network helps show where William M. Sikov may publish in the future.

Co-authorship network of co-authors of William M. Sikov

This figure shows the co-authorship network connecting the top 25 collaborators of William M. Sikov. A scholar is included among the top collaborators of William M. Sikov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William M. Sikov. William M. Sikov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Braunstein, Lior Z., Melissa P. Mitchell, Hanna Bandos, et al.. (2025). NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncology. 21(16). 2017–2025.
2.
Fernández-Martínez, Aranzazu, Cheng Fan, Adam D. Pfefferle, et al.. (2025). Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. npj Breast Cancer. 11(1). 24–24.
3.
Abu‐Khalaf, Maysa, Christos Hatzis, Elisa Baldelli, et al.. (2023). AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. npj Precision Oncology. 7(1). 18–18. 21 indexed citations
4.
Cole, Bernard F., et al.. (2022). Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis. Breast Cancer Targets and Therapy. Volume 14. 63–70. 2 indexed citations
5.
Thompson, Kevin J., Roberto A. Leon‐Ferre, Jason P. Sinnwell, et al.. (2022). Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 4(2). zcac018–zcac018. 26 indexed citations
6.
Strenger, Rochelle, Robert D. Legare, Mary Anne Fenton, et al.. (2021). Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. Breast Cancer Research and Treatment. 189(1). 93–101. 2 indexed citations
7.
Braman, Nathaniel, Prateek Prasanna, Jon Whitney, et al.. (2019). Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancer. JAMA Network Open. 2(4). e192561–e192561. 235 indexed citations breakdown →
8.
Brodsky, Alexander S., Dongfang Yang, Christoph Schorl, et al.. (2016). Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer. 16(1). 274–274. 38 indexed citations
9.
Warner, Erica T., Karla V. Ballman, Carrie Strand, et al.. (2016). Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Research and Treatment. 159(1). 109–118. 43 indexed citations
10.
Golshan, Mehra, Constance Cirrincione, William M. Sikov, et al.. (2016). Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment. 160(2). 297–304. 60 indexed citations
11.
Varadan, Vinay, Hannah Gilmore, Kristy Miskimen, et al.. (2016). Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clinical Cancer Research. 22(13). 3249–3259. 75 indexed citations
12.
Varadan, Vinay, Sitharthan Kamalakaran, Hannah Gilmore, et al.. (2015). Brief‐exposure to preoperative bevacizumab reveals a TGF‐β signature predictive of response in HER2‐negative breast cancers. International Journal of Cancer. 138(3). 747–757. 14 indexed citations
13.
Abu‐Khalaf, Maysa, Sarah S. Mougalian, Tara Sanft, et al.. (2015). A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).. Journal of Clinical Oncology. 1 indexed citations
14.
Sikov, William M., Donald A. Berry, Charles M. Perou, et al.. (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 33(1). 13–21. 650 indexed citations breakdown →
15.
Perez, Kimberly, William M. Sikov, Matthew Vrees, et al.. (2014). Complete Neoadjuvant Treatment for Rectal Cancer. American Journal of Clinical Oncology. 40(3). 283–287. 48 indexed citations
16.
Cheng, Huan, Yalai Bai, William M. Sikov, et al.. (2014). Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 14(1). 326–326. 19 indexed citations
17.
Olszewski, Adam J., Yazan Migdady, Susan K. Boolbol, et al.. (2013). Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Research and Treatment. 138(1). 215–223. 21 indexed citations
18.
Migdady, Yazan, et al.. (2013). Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes. The Breast. 22(5). 793–798. 14 indexed citations
19.
Reeder‐Hayes, Katherine E., Lisa A. Carey, & William M. Sikov. (2011). Clinical trials in triple negative breast cancer. Breast Disease. 32(1-2). 123–136. 22 indexed citations
20.
Sikov, William M., et al.. (2000). Splenosis presenting as occult gastrointestinal bleeding. American Journal of Hematology. 65(1). 56–61. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Günther Gruber Breakdown of academic impact, for papers by Frédérique Penault–Llorca Breakdown of academic impact, for papers by Yasuaki Sagara Breakdown of academic impact, for papers by Malcolm Hayes Breakdown of academic impact, for papers by Tibor Tot Breakdown of academic impact, for papers by Maria Schwaederlé Breakdown of academic impact, for papers by Yun Gong Breakdown of academic impact, for papers by Charles Coutant Breakdown of academic impact, for papers by Takayuki Kinoshita Breakdown of academic impact, for papers by C. Bourgier
Rankless by CCL
2026